pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Trodelvy · news · pharmadog
← back to Trodelvy
News mentioning Trodelvy
37
stories
25d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
Sep 11, 26
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
Sep 9, 26
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 9, 26
Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
endpoints
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 12, 26
Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
onclive
May 12, 26
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
onclive
May 11, 26
Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
onclive
May 11, 26
MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
onclive
May 11, 26
Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
onclive
May 11, 26
Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection
onclive
May 11, 26
Expanding ctDNA Applications to RCC and Germ Cell Tumors
onclive
May 11, 26
RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
onclive
May 11, 26
ctDNA in Metastatic Urothelial Carcinoma
onclive
May 11, 26
Institutional Perspectives on Treatment Thresholds in PLGG
onclive
May 11, 26
Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups
onclive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 9, 26
The OncFive: Top Oncology Articles for the Week of 5/3
onclive
May 8, 26
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
onclive
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 8, 26
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
onclive
May 8, 26
Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
onclive
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
May 7, 26
Dr Mauro on the Significance of Alternative TKI Formulations in CML
onclive
May 7, 26
Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
onclive
May 7, 26
Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.
onclive
← prev
page 1 of 2
next →
